Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of Antisense Oligonucleotides in Duchenne Muscular Dystrophy

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Subject is male ≥ 10 years and ≤ 17 years of age at the time of study drug administration.~2. Subject has clinical diagnosis compatible with Duchenne's Muscular Dystrophy (DMD) and evidence of mutational and dystrophin defects from muscle biopsy consistent with DMD (out-of frame deletions, absent dystrophin).Eligible deletions are those that can be rescued by the skipping of exon 51 \[45-50; 47-50; 48-50; 49-50; 50; 52; 52-63\].~3. Subject has had a muscle biopsy analysed, showing \<5% revertant fibres present. Biopsy may be collected at the time of DMD diagnosis or as part of protocol screening procedures.~4. Subject is unable to ambulate or stand independently.~5. Subject has Stage 1 to 3 EDB muscle preservation determined by MRI.~6. Subject has a forced vital capacity ≥ 25% confirmed within 3 months from Day One.~7. Subject has mean oxygen saturation monitoring \> 94% in overnight domiciliary overnight sleep study within 3 months of Day One.~8. Subject has the ability to comply with all study evaluations and return for all study.~9. Subject and parent have psychiatric adjustments, adequately supportive psychosocial circumstances and a full understanding of study aims process and likely outcomes.~Exclusion Criteria:~1. Subject has had external digitorum brevis (EDB) muscle removed.~2. Subject has Stage 4 EDB muscle preservation determined by MRI.~3. Subject has a left ventricular shortening fraction of \< 25% and/or an ejection fraction of \< 35% by echocardiography at visit one or within three months of visit one.~4. Subject has evidence of nocturnal hypoventilation (mean oxygen saturation at night of ≤ 94%) confirmed via overnight sleep study at Visit One (as screening procedure) or within 3 months of Visit One by overnight sleep study.~5. Subject has severe respiratory insufficiency defined by the need for invasive or non-invasive mechanical ventilation (does not include nocturnal ventilatory support).~6. Subject has severe cognitive dysfunction rendering them unable to understand and collaborate with study protocol.~7. Subject has immune deficiency or autoimmune disease.~8. Subject has a known bleeding disorder or has received chronic anticoagulant treatment within three months of study entry.~9. Subject has received pharmacologic treatment, apart from corticosteroids, that might affect muscle strength or function within 8 weeks of study entry (viz.,anabolic steroids, creatine protein supplementation, albuterol or other beta agonists).~10. Subject has had surgery within 3 months of study entry or planned for anytime during study.~11. Subject has active significant illness at time of study entry.~12. Subject has is unable to undergo MRI testing (viz., has metal implants).~13. Subject or parent has active psychiatric disorder, has adverse psychosocial circumstances, recent significant emotional loss, history of depressive or anxiety disorders that might interfere with protocol completion or compliance.~14. Subject has any known allergies to products likely to be used in the study (viz.,antiseptics, anaesthetics).~15. Subject has used any experimental treatments or has participated in any clinical trial within 4 weeks of study entry.~16. Subject has used intranasal, inhaled or topical steroids for a condition other than muscular dystrophy within 1 weeks of study entry.

- Gender: MALE
- Minimum Age: 10 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Low dose (Type: EXPERIMENTAL): Low dose of AVI-4658
- High dose (Type: EXPERIMENTAL): High dose of AVI-4658

Based on this trial design, predict the completion outcome and termination type (if applicable).